MAPT and supranuclear palsy, progressive, 1: Our cohort included 92 patients, 37/92 (40.2%) with FTLD-Tau (11 CBD, 5 MAPT, 12 PiD and 9 PSP) and 55/92 (59.8%) with FTLD-TDP (20 type A, 17 type B, 13 type C, 5 Type E).